Jobs — and national identity — top French concerns over the news that pharmaceutical company Sanofi plans to sell 50% of ...
Sanofi announced on Monday that it had entered into exclusive negotiations with US investment fund CD&R to sell it a majority ...
GlobalData on MSN10d
Sanofi’s $17bn sale of Opella to US investors advances following government dealA stake by France-owned Bpifrance and promise of local job retention have allayed political backlash over the sale of ...
French pharamceutical giant Sanofi has confirmed plans to sell a controlling stake in its over-the-counter unit to a US ...
11d
The proposed sale turned into a real political issue because Opella's products include Doliprane, the best-selling medicine ...
The sale of a French drugmaker to an American group is likely to now go ahead after French Economy Minister Antoine Armand ...
The sale of a controlling 50-percent stake in Opella to CD&R values the maker of France's leading painkiller, Doliprane, at ...
French drugmaker Sanofi's announcement that it will sell a controlling stake in its consumer health division to a U.S.
Le Doliprane est un médicament à base de paracétamol, le plus vendu en France, utilisé pour soulager la douleur et lutter ...
C’est une opération surveillée de toute part. D’ici le deuxième trimestre 2025, Sanofi se séparera de sa filiale "grand public", Opella, qui produit notamment le Doliprane.
La grève contre la cession des sites de production du Doliprane en France est reconduite mardi à Lisieux mais suspendue à ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback